ArticleInternational journal of ophthalmology2025
Identifying predictors of visual improvement in ethambutol optic neuropathy: insights from a 5-year retrospective analysis in a tertiary clinic in Indonesia.
Article in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ocular toxicity associated with Ethambutol in the South-East Asia Region.International ophthalmology · 2026Observational
- Longitudinal Observation by Optical Coherence Tomography in Patients Treated with Ethambutol: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo characterize the demographic and clinical features of ethambutol optic neuropathy (EON) in an Indonesian patient population and explore prognostic factors for visual recovery.
methodsRetrospective study of 58 EON patients at an Indonesian eye center (2017-2022). Demographics, ethambutol treatment, ophthalmologic findings were collected. Visual outcomes after ethambutol cessation assessed at 3-12mo. Patients categorized as having visual improvement (≥2 Snellen lines and/or >5° visual field gain) or no improvement.
resultsMean age was 55.5±12.9y, with 56.9% females. Median duration of ethambutol use was 9mo (range: 2-20) at a mean daily dose of 19.7±5.3 mg/kg. At presentation, mean visual acuity was 1.3 logMAR (range: 0-2.5), with normal fundus appearance in 72.4% of eyes. The most common visual field defect was generalized depression (52.4%). After ethambutol cessation, 56.9% of patients had visual improvement. Younger age (50.24±13.8y
conclusionOver half experience visual recovery after ethambutol cessation. Younger age, lower cumulative dose, absence of hypertension or kidney disease predict better visual outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.